Gelonghui, April 18 | Jianshi Technology-B (9877.HK) saw a sharp rise in sales today. It rose by more than 24% in the afternoon, hitting a high of HK$4.48, and the turnover exceeded HK$42 million. Recently, Jianshi Technology released its 2023 financial report. The net loss due to mother narrowed to 372 million yuan, and the book capital was 928 million yuan, an increase of 27.6% over the previous year. As far as the company's core products are the LUX-Valve series products of the tricuspid valve interventional catheter replacement system, in the domestic market, the company is currently actively promoting the LUX-Valve listing registration process. As a second-generation transcatheter tricuspid valve replacement system, LUX-VALVE Plus has now completed confirmatory clinical trial enrollment and registered clinical follow-up for 6 months, and it is expected that an application for marketing registration will also be submitted in the near future. LUX-VALVE Plus is also advancing overseas, and several milestones are expected to occur in 2024.